Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Larimar Therapeutics (LRMR) Payables (2016 - 2020)

Larimar Therapeutics (LRMR) has disclosed Payables for 7 consecutive years, with $10.6 million as the latest value for Q3 2019.

  • For the quarter ending Q3 2019, Payables fell 54.2% year-over-year to $10.6 million, compared with a TTM value of $10.6 million through Sep 2019, down 54.2%, and an annual FY2018 reading of $9.0 million, down 60.71% over the prior year.
  • Payables was $10.6 million for Q3 2019 at Larimar Therapeutics, up from $9.3 million in the prior quarter.
  • Across five years, Payables topped out at $24.0 million in Q1 2018 and bottomed at $3.9 million in Q3 2017.
  • Average Payables over 5 years is $9.7 million, with a median of $7.0 million recorded in 2015.
  • Peak annual rise in Payables hit 486.38% in 2018, while the deepest fall reached 60.71% in 2018.
  • Year by year, Payables stood at $10.4 million in 2015, then tumbled by 40.94% to $6.2 million in 2016, then soared by 273.64% to $23.0 million in 2017, then plummeted by 60.71% to $9.0 million in 2018, then increased by 17.1% to $10.6 million in 2019.
  • Business Quant data shows Payables for LRMR at $10.6 million in Q3 2019, $9.3 million in Q2 2019, and $10.4 million in Q1 2019.